HSBC upgraded Eli Lilly (LLY) to Hold from Reduce with a $700 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Novo Nordisk Stock (NVO) Slides on Rival Weight Loss Pill News
- Eli Lilly (LLY) Prepares for Weight Loss Pill Approval After Late-Stage Clinical Trial
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Closing Bell Movers: MongoDB jumps nearly 30% after beat and raise
- Eli Lilly & Co’s Orforglipron Shows Promising Phase III Trial Results, Boosting Buy Rating